Breast and ovarian cancer vaccines
The compositions described herein include an epitope of a peptide that may elicit an immune response in a subject following administration. The compositions may comprise nucleic acids. The compositions may comprise peptides. The methods described herein include administering a composition comprising an epitope of a peptide to a subject in need thereof.
1. A method of treating a breast or ovarian cancer in a subject in need thereof, the method comprising:
administering a composition comprising the fusion protein of SEQ ID NO: 89 to the subject, wherein the composition induces an immune response to breast or ovarian cancer cell in the subject.
2. The method of claim 1 , wherein the immune response is a Type I immune response.
3. The method of claim 1 , wherein the immune response is characterized by a ratio of Type I cytokine production to Type II cytokine production that is greater than 1.
4. The method of claim 1 , wherein the immune response is characterized by a ratio of IFNg production to IL-10 production that is greater than 1.
5. The method of claim 1 , wherein the cancer is breast cancer.
6. The method of claim 1 , wherein the cancer is ovarian cancer.
7. The method of claim 1 , wherein the composition further comprises a pharmaceutically acceptable carrier, an adjuvant, a chemotherapeutic agent, or a combination thereof.
8. The method of claim 7 , wherein the adjuvant is GM-CSF.
9. The method of claim 7 , wherein the chemotherapeutic agent is cisplatin.